STOCK TITAN

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced that CEO Eric Easom will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 5:00 p.m. ET. This virtual event focuses on the company's efforts to develop treatments for serious infectious diseases, particularly their lead candidate epetraborole, designed to treat NTM lung disease. A webcast of the presentation will be available in the Investors section of their website, with archived access for 30 days post-event.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference.

Details of the event is as follows:

SVB Securities Global Biopharma Conference, February 14-15, 2023 (virtual)

  • Eric Easom, Co-Founder, President and CEO will present a corporate overview on Tuesday, February 14 at 5:00 p.m. ET.

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

COMPANY CONTACT:

Lucy O. Day

Chief Financial Officer

l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:

Anne Bowdidge

ir@an2therapeutics.com

Source: AN2 Therapeutics, Inc.

FAQ

What is AN2 Therapeutics presenting at the SVB Securities Global Biopharma Conference?

AN2 Therapeutics is presenting a corporate overview at the SVB Securities Global Biopharma Conference on February 14, 2023.

When will Eric Easom present at the SVB Securities Global Biopharma Conference?

Eric Easom will present on February 14, 2023, at 5:00 p.m. ET.

How can I access the AN2 Therapeutics presentation?

The presentation can be accessed via a webcast on the AN2 Therapeutics website, with an archived replay available for 30 days.

What is the focus of AN2 Therapeutics' research?

AN2 Therapeutics focuses on developing treatments for rare and serious infectious diseases, particularly NTM lung disease.

What is epetraborole?

Epetraborole is AN2 Therapeutics' lead candidate, being studied as a once-daily oral treatment for NTM lung disease.

AN2 Therapeutics, Inc.

NASDAQ:ANTX

ANTX Rankings

ANTX Latest News

ANTX Stock Data

38.84M
23.24M
21.64%
52.31%
0.45%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MENLO PARK